Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Código QR

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Müller HHO, Moeller S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	drug-induced schizophrenia negative symptoms side effects weight cardiac safety Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/17fd112a29384befb7777c2684f485e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes JM, et al.
Publicado: (2021)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits
por: Lijuan Huo, et al.
Publicado: (2021)

Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS)
por: Raimo K. R. Salokangas, et al.
Publicado: (2021)

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
por: Somaieh Ashrafi, et al.
Publicado: (2022)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS)
por: Hashimoto N, et al.
Publicado: (2019)

Validation of the Chinese Version of the 16-Item Negative Symptom Assessment
por: Huang B, et al.
Publicado: (2020)

Relationship Between Cognitive and Clinical Insight at Different Durations of Untreated Attentional Psychotic Symptoms in High-Risk Individuals
por: LiHua Xu, et al.
Publicado: (2021)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Validation of the Dutch Version of the Brief Negative Symptom Scale
por: Seelen-de Lang BL, et al.
Publicado: (2020)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll CU, et al.
Publicado: (2019)

Online Left-Hemispheric In-Phase Frontoparietal Theta tACS for the Treatment of Negative Symptoms of Schizophrenia
por: Chuan-Chia Chang, et al.
Publicado: (2021)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Suicidality, self-stigma, social anxiety and personality traits in stabilized schizophrenia patients – a cross-sectional study
por: Vrbova K, et al.
Publicado: (2018)

Relationship between social and cognitive functions in people with schizophrenia
por: Tominaga T, et al.
Publicado: (2018)

Influence of CFH gene on symptom severity of schizophrenia
por: Zhang C, et al.
Publicado: (2017)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose M, et al.
Publicado: (2021)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts RJ, et al.
Publicado: (2016)

Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2016)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
por: Zhang Z, et al.
Publicado: (2018)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome L
Publicado: (2018)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
por: Zhuo K, et al.
Publicado: (2019)

The Effects of Recreation Therapy on the Habit of Smoking and Positive–Negative Symptoms Among Patients with Chronic Schizophrenia
por: Pirbalouti M. G., et al.
Publicado: (2017)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Patrick Köck, et al.
Publicado: (2021)

Use of atypical antipsychotics in the elderly: a clinical review
por: Gareri P, et al.
Publicado: (2014)

Development of psychotic symptoms following ingestion of small quantities of alcohol
por: Lu DL, et al.
Publicado: (2016)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy Á, et al.
Publicado: (2021)

Employment-Related Factors of Forensic Psychiatric Outpatients with Psychotic Disorders
por: Takeda K, et al.
Publicado: (2019)

Highly Suspected COVID-19 Cluster with Multiple Negative SARS-CoV-2 RNA Tests: A Case Report
por: Huang X, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
por: Barabássy Á, et al.
Publicado: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Diagnostic pitfalls in a young Romanian ranger with an acute psychotic episode
por: Nagy EE, et al.
Publicado: (2016)

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
por: Dayabandara M, et al.
Publicado: (2017)

Prospective memory in non-psychotic first-degree relatives of patients with schizophrenia: a meta-analysis
por: Lin SZ, et al.
Publicado: (2019)

Ear symptoms in patients with orofacial pain and dysfunction ‐ An explorative study on different TMD symptoms, occlusion and habits
por: Christina Mejersjö, et al.
Publicado: (2021)